All In Biotech

Drug Trial Radar · NCT03069469

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 16, 2017

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.

Conditions

  • Advanced Malignant Neoplasm
  • Pigmented Villonodular Synovitis
  • Giant Cell Tumor of Tendon Sheath
  • Tenosynovial Giant Cell Tumor
  • Tenosynovial Giant Cell Tumor, Diffuse

Interventions

  • VimseltinibDrug

    Colony-stimulating factor 1 receptor (CSF1R) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: Day 1 - Day 28 of Cycle 1 for each dose level tested
  2. Number of Patients with Dose-Limiting Toxicities (DLTs)Time frame: Day 1- Day 28 of Cycle 1 for each dose level tested
  3. Time to maximum observed concentration of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
  4. Maximum observed concentration of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
  5. Trough observed concentration of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
  6. Area under the concentration-time curve (AUC) of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
  7. Half life of VimseltinibTime frame: Cycle 1 Day 1 and Day 8, and Cycle 2 Day 1 (pre-dose and at multiple time points (up to 8 hours) post-dose)
  8. Objective response rate (ORR= complete response [CR]+partial response [PR]) (Expansion Phase only)Time frame: At Week 25 (Cycle 7, Day 1)
  9. Duration of response rate (DOR) (Expansion Phase only)Time frame: Date from PR or CR to disease progression or death (Estimated up to 24 months)

Locations

24 sites in 9 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Palo Alto, California

  • University of Colorado - Denver

    Denver, Colorado

  • Mayo Clinic

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Dana Farber

    Boston, Massachusetts

  • MSKCC

    New York, New York

  • OHSU

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Princess Margaret Cancer Center

    Toronto, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Centre Leon Berard

    Lyon, France

  • Gustave Roussy Cancer Campus Grand Paris

    Paris, France

  • IRCCS Istituto Ortopedico Rizzoli

    Bologna, Italy

  • Fondazione IRCCS Istituto Nazionale Dei Tumori

    Milan, Italy

  • Istituto Nazionale dei Tumori

    Milan, Italy

  • Regina Elena National Cancer Institute

    Rome, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • M. Sklodowska-Curie Memorial Cancer Center

    Warsaw, Poland

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario Virgen del Rocío, Sevilla

    Seville, Spain

  • University College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.